PT3865155T - Processo para modificação específica de local de um anticorpo - Google Patents

Processo para modificação específica de local de um anticorpo

Info

Publication number
PT3865155T
PT3865155T PT203051388T PT20305138T PT3865155T PT 3865155 T PT3865155 T PT 3865155T PT 203051388 T PT203051388 T PT 203051388T PT 20305138 T PT20305138 T PT 20305138T PT 3865155 T PT3865155 T PT 3865155T
Authority
PT
Portugal
Prior art keywords
antibody
site
specific modification
modification
specific
Prior art date
Application number
PT203051388T
Other languages
English (en)
Original Assignee
Orano Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orano Med filed Critical Orano Med
Publication of PT3865155T publication Critical patent/PT3865155T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT203051388T 2020-02-13 2020-02-13 Processo para modificação específica de local de um anticorpo PT3865155T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20305138.8A EP3865155B1 (en) 2020-02-13 2020-02-13 Process for site-specific modification of an antibody

Publications (1)

Publication Number Publication Date
PT3865155T true PT3865155T (pt) 2023-01-02

Family

ID=69740312

Family Applications (1)

Application Number Title Priority Date Filing Date
PT203051388T PT3865155T (pt) 2020-02-13 2020-02-13 Processo para modificação específica de local de um anticorpo

Country Status (15)

Country Link
US (1) US20230120220A1 (pt)
EP (1) EP3865155B1 (pt)
JP (1) JP7671768B2 (pt)
KR (1) KR20220140803A (pt)
CN (1) CN115175708B (pt)
AU (1) AU2021220275A1 (pt)
BR (1) BR112022015765A2 (pt)
CA (1) CA3166956A1 (pt)
ES (1) ES2934984T3 (pt)
FI (1) FI3865155T3 (pt)
IL (1) IL295163A (pt)
PL (1) PL3865155T3 (pt)
PT (1) PT3865155T (pt)
WO (1) WO2021160724A1 (pt)
ZA (1) ZA202208650B (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1738640A (zh) * 2002-11-18 2006-02-22 马克西根公司 干扰素-α多肽和偶联物
EP3179252B1 (en) * 2004-07-30 2018-11-14 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
ES2582652T3 (es) * 2006-02-10 2016-09-14 Genentech, Inc. Anticuerpos anti-FGF19 y métodos de uso de los mismos
WO2010059315A1 (en) * 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2012142659A1 (en) * 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
US9701753B2 (en) * 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
SG11201706849SA (en) * 2015-02-26 2017-09-28 Sciencons AS Radiopharmaceutical solutions with advantageous properties
ES2855998T3 (es) 2015-08-07 2021-09-27 Merck Patent Gmbh Etiqueta transglutamina para bioconjugación específica de sitio eficiente
EP3272864A1 (en) * 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
NZ762376A (en) * 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
EP3773670A4 (en) * 2018-04-05 2022-03-09 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof

Also Published As

Publication number Publication date
CA3166956A1 (en) 2021-08-19
ES2934984T3 (es) 2023-02-28
EP3865155A1 (en) 2021-08-18
FI3865155T3 (fi) 2023-01-13
JP2023513804A (ja) 2023-04-03
PL3865155T3 (pl) 2023-01-30
US20230120220A1 (en) 2023-04-20
ZA202208650B (en) 2023-04-26
KR20220140803A (ko) 2022-10-18
IL295163A (en) 2022-09-01
JP7671768B2 (ja) 2025-05-02
EP3865155B1 (en) 2022-11-30
WO2021160724A1 (en) 2021-08-19
BR112022015765A2 (pt) 2022-10-11
AU2021220275A1 (en) 2022-09-08
CN115175708A (zh) 2022-10-11
CN115175708B (zh) 2023-07-18

Similar Documents

Publication Publication Date Title
NZ714079A (en) Purification process for monoclonal antibodies
EP3939453A4 (en) PREHEATING METHOD FOR AN ELECTRONIC CIGARETTE
IL292210A (en) An efficient process for the synthesis of 2-amino-5-chloro-n,3-dimethylbenzamide
IL285768A (en) Methods for use in generating organoids for high-throughput drug screening
GB202306569D0 (en) Process for cracking ammonia
IL279528A (en) A method for producing a controlled mixture of two or more different antibodies
EP3774285C0 (en) METHOD AND APPARATUS FOR FORMING AN OBJECT USING ADDITIVE MANUFACTURING
ZA201908294B (en) Method for preparing transmission electron microscope sample of powder particles
GB201704115D0 (en) Method of selecting for antibodies
ZA202200018B (en) Method for synthesizing m-methoxyphenol
ZA202208650B (en) Process for site-specific modification of an antibody
IL308393A (en) Antibodies for the treatment of alpha-synuclein diseases
GB202008860D0 (en) BTLA antibodies
HUP2100414A1 (hu) Eljárás bioadszorbens anyag elõállítására
EP3924985C0 (de) Spule und verfahren zur herstellung der spule
HUE067878T2 (hu) Eljárás alkilamidotiazolok gyártásához
EP4291568A4 (en) METHODS FOR PURIFICATION OF MONOCLONAL ANTIBODIES
GB201812056D0 (en) Method of an apparatus for producing nanomaterials
IL316018A (en) IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB
ZA202107520B (en) Method for producing carbon-based products from secondary raw materials containing ph regulators
GB201914819D0 (en) Method of selecting for antibodies
GB201913333D0 (en) Method of selecting for antibodies
GB201903270D0 (en) Method of selecting for antibodies
GB201903233D0 (en) Method of selecting for antibodies
ZA202106657B (en) Binder for an agglomeration process